Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer – guidance (TA654)
Osimertinib is recommended as an option for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.
Source:
National Institute for Health and Care Excellence